-
公开(公告)号:WO2019170904A1
公开(公告)日:2019-09-12
申请号:PCT/EP2019/055947
申请日:2019-03-11
申请人: GRÜNENTHAL GMBH
IPC分类号: C07D401/14 , C07D401/04 , C07D401/12 , C07D409/12 , C07D417/12 , C07D417/14 , C07D211/58 , C07D211/76 , A61K31/451 , A61K31/4535 , A61K31/4545 , A61P29/00
摘要: The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.
-
2.
公开(公告)号:WO2018054549A1
公开(公告)日:2018-03-29
申请号:PCT/EP2017/025264
申请日:2017-09-21
申请人: GRÜNENTHAL GMBH
发明人: JAKOB, Florian , NORDHOFF, Sonja , RIDER, David , WAGENER, Markus , BAHRENBERG, Gregor , DUNKERN, Torsten
IPC分类号: C07D401/12 , A61K31/445 , A61K31/45 , A61K31/4545 , C07D211/16 , C07D211/56 , C07D211/94
摘要: The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.
摘要翻译: 本发明涉及通式(I)的化合物,其充当FPR2的调节剂并且可用于治疗和/或预防至少部分由FPR2介导的病症 p>
-
公开(公告)号:WO2018234354A1
公开(公告)日:2018-12-27
申请号:PCT/EP2018/066357
申请日:2018-06-20
申请人: GRÜNENTHAL GMBH
发明人: KONETZKI, Ingo , JAKOB, Florian , WAGENER, Markus , DUNKERN, Torsten , RIDER, David , WELBERS, André
IPC分类号: C07D401/14 , C07D403/04 , C07D471/04 , A61K31/505 , A61K31/5377 , A61P25/00 , A61P29/00
摘要: The invention relates to novel 3-indole and 3-indazole compounds characterized in that the compound has general formula (I) in which the chemical groupings, substituents. variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
-
公开(公告)号:WO2018234353A1
公开(公告)日:2018-12-27
申请号:PCT/EP2018/066355
申请日:2018-06-20
申请人: GRÜNENTHAL GMBH
IPC分类号: C07D401/14 , C07D401/04 , A61K31/444 , A61K31/4439 , A61P29/00 , A61P25/00
摘要: The invention relates to novel indole and indazole compounds characterized in that the compound has general formula (I), in which the chemical groupings, substituents, variables and indices are as defined in the description, and to their use as medicaments, in particular as medicaments for the treatment of conditions and diseases that can be treated by inhibition of the PDE4 enzyme.
-
-
-